Impact of Virtual Reality Hypno-sedation on Functional Recovery and Anxiety in Foot Surgery With Regional Anesthesia

Sponsor
University of Liege (Other)
Overall Status
Recruiting
CT.gov ID
NCT05558449
Collaborator
(none)
57
1
3
9.6
6

Study Details

Study Description

Brief Summary

This prospective study aims to evaluate whether the implementation of a virtual reality hypnosedation (VRH)protocol reduces preoperative anxiety and increases patient comfort before, during, and after outpatient foot surgery.

Condition or Disease Intervention/Treatment Phase
  • Device: Hypnosedation
  • Drug: Midazolam injection
  • Device: Virtual reality
Phase 4

Detailed Description

This prospective study aims to evaluate whether the implementation of a virtual reality hypnosedation (VRH) protocol reduces preoperative anxiety and increases patient comfort before, during, and after outpatient foot surgery. The investigators hope to demonstrate a reduction in anxiety, improved postoperative experience and functional recovery according to currently validated scores measuring preoperative and postoperative recovery, anxiety and stress, and experience during a regional anesthesia technique.

The investigators expect that VRH will be more effective than VR alone and conventional pharmacological sedation in reducing preoperative anxiety and in improving experience and functional recovery. If the hypothesis is correct, the investigators could propose to integrate this protocol as a first line in the ambulatory management of elective foot surgery.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
57 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective Randomized Clinical TrialProspective Randomized Clinical Trial
Masking:
None (Open Label)
Masking Description:
Open
Primary Purpose:
Treatment
Official Title:
Impact of Virtual Reality Hypno-sedation on Functional Recovery and Anxiety in Foot Surgery With Regional Anesthesia: a Randomized Clinical Trial.
Actual Study Start Date :
Dec 14, 2022
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Oct 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: VR

Patients in the VR group (19 patients) will receive VR alone without hypnosedation. The VR headset will be used on these patients without an external voice or device allowing hypnosis. The VR module used will be "Silva", i.e. a scenario of a walk in the forest through the 4 seasons.

Device: Virtual reality
Only virtual reality without a hypnosedation session. The virtual reality headset will be used on these patients without external voice or hypnosis device. The virtual reality module used will be "Silva", i.e. a scenario of a walk in the forest through the 4 seasons.

Experimental: VRH

The patients in the VRH group (19 patients) will benefit from a hypnosedation session with a VRH headset during the local anesthesia technique and during the surgery (approximately 60 minutes). The VRH module used will be "Silva", i.e. the same scenario of a walk in the forest through the 4 seasons with a voice accompanying the hypnosis session.

Device: Hypnosedation
Hypnosedation session with a virtual reality headset during the regional anesthesia technique and during the surgery (approximately 60 minutes). The VRH module used will be "Silva", i.e. the same scenario of a walk in the forest through the 4 seasons with a voice accompanying the hypnosis session.

Active Comparator: C

Patients in group C (control group, 19 patients) will receive only midazolam-based pharmacological sedation. This will be administered with intermittent boluses of 1 mg until patient comfort and sedation on the Richmond analgo-sedation scale (RASS) of -3 (response to verbal stimulus) is achieved.

Drug: Midazolam injection
Midazolam intravenous injection 1 mg until RASS -3

Outcome Measures

Primary Outcome Measures

  1. (Evaluation du Vecu de l'Anesthesie LocoRegionale) EVAN-LR [4 hours after surgery]

    The primary endpoint will be the EVAN-LR score as a measure of intraoperative experience. EVAN-LR: a 0-100 scale, with 100 indicating the best possible level of satisfaction and 0 the worst.

Secondary Outcome Measures

  1. Anxiety [5 minutes after the end of the surgery]

    Numeric rating scale (NRS) (0 to 10) for pre- and postoperative anxiety

  2. Quality of Recovery- 15 items (QoR-15) [1 day before, 1 and 3 day after surgery]

    Assessment of the QoR-15 score on postoperative functional recovery and the variation in time between the day before surgery, the day after and 3 days after surgery

  3. Length of surgery [5 minutes after the end of the surgery]

    Length of surgery procedure in minutes

  4. Complications [6 hours after surgery]

    The occurrence of complications related to the techniques used

  5. VRH complications [6 hours after surgery]

    The occurrence of side effects related to virtual reality (nausea, paradoxical anxiety, dizziness, etc.)

  6. Time perception [5 minutes after the end of the surgery]

    Perception of the duration of the surgery during the VRH.

  7. Surgeon satisfaction [5 minutes after the end of the surgery]

    Surgeon satisfaction on a numeric rating scale from 0 to 10

  8. Dissociation [5 minutes after the end of the surgery]

    The Numeric rating scale (NRS) (0-10) dissociation for the assessment of dissociation during the surgery

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Major patients, classified as ASA 1-2-3, admitted for foot surgery (metatarsophalangeal arthrodesis or hallux valgus cure), under peripheral locoregional anesthesia (sciatic nerve block at popliteal level).
Exclusion Criteria:
  • pregnant women

  • patients with peripheral neuropathy or other severe neurological pathology

  • allergy or contraindication to local anesthetics or benzodiazepines

  • chronic renal failure or severe hepatic failure

  • major hemostasis disorders

  • severe vision or hearing problems that would render the VR and VRH device useless or unusable, and patient contraindication or refusal to use the VRH headset, such as claustrophobia or kinesiophobia.

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU de Liège Liège Belgium 4000

Sponsors and Collaborators

  • University of Liege

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Michele Carella, Head of Clinic, Anesthesiology and Intensive Care Department, University of Liege
ClinicalTrials.gov Identifier:
NCT05558449
Other Study ID Numbers:
  • VRH.foot
First Posted:
Sep 28, 2022
Last Update Posted:
Dec 16, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 16, 2022